Access read The question this study is designed to answer is not clinical, it is commercial, and the design says so. TriClip is approved, its pivotal trial is done, and a 3,035-patient registry has already shown the real-world results track the trial. What remains unresolved is durability and long-term outcome, and those are the two things payers and guideline committees ask for before a device moves from covered-with-restrictions to standard of care. Five years of follow-up across 100 sites in three jurisdictions is exactly the shape of a coverage file, not a scientific question. Note what the design cannot do: without a randomised comparator it can describe how patients fare, but it cannot settle whether TriClip extends life against medical therapy, which has been the persistent criticism of transcatheter repair in the tricuspid position. The one part that could genuinely change the argument is the reverse-remodelling sub-study, because reversing structural cardiac change is a mechanistic claim rather than a symptomatic one, and a device that demonstrably reverses remodelling is arguing for disease modification. That sub-study is the piece to watch. The rest is the file being built.